MET233 and MET097

Phase 2

PFIZER (PFE)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q1 '27

PFEPhase 2$160.0B

MET233 and MET097 Phase 2 Est. Readout

MET233 and MET097• Obesity and Obesity-related Medical Conditions132

Q1 2027~QConfirmedSTALE

CT.gov

00%

Development History

Sep '26

PFEPhase 2$160.0B

MET233 and MET097 Phase 2 Est. Readout

MET233 and MET097• Obesity and Obesity-related Medical Conditions381

Sep 2026~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Obesity and Obesity-related Medical Conditions

View Full Landscape

Drug Information

Target Indication

Obesity and Obesity-related Medical Conditions

Clinical Trial

NCT06924320

Last updated: 3/4/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

FSME-IMMUN NEW 0.25 mlPhase 3

Tick-borne Encephalitis

AvelumabPhase 3

Urothelial Cancer

HibPhase 3

Pneumococcal Infections

Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)Phase 3

Pneumococcal Disease

ElotuzumabPhase 3

Multiple Myeloma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts